Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 14, 2014; 20(2): 346-362
Published online Jan 14, 2014. doi: 10.3748/wjg.v20.i2.346
Published online Jan 14, 2014. doi: 10.3748/wjg.v20.i2.346
Intervention | Study design | Sample size | Outcome | Ref. |
Peppermint oil | Randomized, double-blind, placebo-controlled study | 99 | Peppermint oil (Colpermin®) group showed significant symptom improvement (P < 0.05) compared to placebo group after 1 mo | [104] |
Peppermint oil | Randomized, placebo-controlled study | 18 | Peppermint oil significantly reduced GI symptoms (P < 0.01) after 3 wk compared to placebo | [106] |
Peppermint oil | Randomized, double-blind. Placebo-controlled study | 57 | Total IBS severity score was significantly decreased after 4 wk of treatment (P < 0.009) and after 2 mo (P < 0.01) in the peppermint oil group compared to placebo | [108] |
Peppermint oil | Randomized, double-blind, placebo-controlled study | 90 | Significant reduction in IBS symptoms, no abdominal pain in more patients in the peppermint oil group compared to placebo (P < 0.001), less severe abdominal pain in peppermint oil group (P < 0.05) in peppermint oil group after 2 mo | [109] |
Peppermint oil | Randomized, double-blind, placebo-controlled study | 65 | Significant reduction in abdominal pain in peppermint oil group compared to placebo group (P < 0.001), but pain score increased 2 wk after completion of trial | [110] |
Artichoke leaf | Post-marketing surveillance | 279 | Significant reduction (P < 0.05) in overall IBS symptoms after 6 wk of treatment | [113] |
Artichoke leaf | Post-marketing surveillance in IBS with concomitant dyspepsia | 209 | Significant reduction in Nepean Dyspepsia Index after 2 mo (P < 0.001) and normalization of bowel pattern (P < 0.001) | [114] |
Turmeric | Partially blinded, randomized, two-dose pilot study | 207 | Reduction in IBS prevalence in both treatment groups (1 or 2 tablets) compared to baseline (P < 0.001) after 2 mo intervention, no significant differences between groups | [116] |
Curcuma and fumitory | Randomized, double-blind, placebo-controlled study | 106 | No significant differences between curcuma, fumitory, and placebo groups in abdominal pain (P = 0.81) and distension (P = 0.48) after 3 mo | [117] |
STW5 | Randomized, double-blind, placebo-controlled study in patients with dyspepsia | 137 | Significant decrease in gastrointestinal symptom score between STW5 and placebo (P < 0.001) | [118] |
STW5 | Randomized, double-blind, placebo-controlled multicenter study in patients with functional dyspepsia | 315 | Significant decrease in gastrointestinal symptom score between STW5 and placebo (P < 0.05) after 2 mo intervention | [119] |
STW5 | Randomized, double-blind, placebo-controlled multicenter study | 203 | Significant reduction in abdominal pain scores for STW5 (P = 0.009) and STW5-II (P = 0.005) and IBS-SSS (P = 0.001 for STW5 and P = 0.0003 for STW5-II) compared to placebo after 4 wk intervention | [120] |
Padma Lax | Randomized, double-blind, placebo-controlled pilot study | 61 | Significant improvement in global IBS symptom scores compared to placebo (P < 0.05) following 3 mo intervention | [123] |
TCM | Randomized, double-blind, placebo-controlled study | 119 | No significant improvements in IBS global symptom score between TCM and placebo group at week 8 (P = 0.38) and week 16 (P = 0.62) | [129] |
- Citation: Grundmann O, Yoon SL. Complementary and alternative medicines in irritable bowel syndrome: An integrative view. World J Gastroenterol 2014; 20(2): 346-362
- URL: https://www.wjgnet.com/1007-9327/full/v20/i2/346.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i2.346